New Delhi: Alembic Pharmaceuticals today said it along with Breckenridge Pharmaceutical Inc, USA has settled patent case with Novartis for Rivastigmine Tartrate capsules used for treating dementia. The companies have settled their Paragraph IV patent litigation with Novartis for Rivastigmine Tartrate capsules which are a generic version of Exelon capsules of Novartis, Alembic Pharmaceuticals said in a filing to BSE. Under the terms of the settlement agreement, Novartis has granted the two companies a licence to market their generic capsules before the date of the patent expiry, it added. The companies will launch the product immediately in the American market, Alembic Pharmaceuticals said.
Telangana: Train, bus collision kills 16
Modi will develop India into Hindu state: Goa Minister
DNA: The unforgettable story of Kargil war
Is BJP trying to develop India as a Hindu nation?